Clinical Competition Candidate
TIVORBEX
TIVORBEX carries product and use-code patents, moderate complexity (2/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 45 months away. Active clinical competition may compress the generic entry window.
LOE window
45months
to latest listed patent expiry (April 23, 2030)
Expiry attractiveness: 4/5
Patent profile
Substance patent (none)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 3
Complexity score: 2/5
Clinical competition
Score: 5/5
Active trials linked: 300
Phase 2/3 trials: 89
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: INDOMETHACIN
Applicant (NDA holder): GENUS LIFESCIENCES INC
Confidence: High